BioNTech
Biotechnology company from Germany / From Wikipedia, the free encyclopedia
BioNTech SE (ˈbaɪɒnˌtek) is a German biotechnology company dedicated to the creation of active immunotherapies for treatments of serious diseases.
Company type | Public (SE) |
---|---|
NASDAQ: BNTX | |
ISIN | US09075V1026 |
Industry | Biotechnology |
Founded | 2008; 16 years ago (2008) |
Founders |
|
Headquarters | , Germany |
Number of locations | 8 (2022) |
Area served | Worldwide |
Key people |
|
Products | BNT162b2 |
Services | Immunotherapy |
Revenue | €17.3 billion (2022) |
€12.6 billion (2022) | |
€9.43 billion (2022) | |
Total assets | €23.3 billion (2022) |
Total equity | €20.1 billion (2022) |
Number of employees | 4,530 (2022) |
Website | biontech |
Footnotes / references Biontech FY 2022 report[1] |
It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases.[2] In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer[3] and Fosun.[4][5] In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country.[6] Later in December 2020 USA,[7] Canada[8] and the EU[9] also gave permission to use the BioNTech vaccine.